Skip to content

KSA: Burjeel Holdings Expands PhysioTherabia Network

Aligned with Saudi Arabia’s Vision 2030 goals, PhysioTherabia promotes optimal physical recovery and overall wellness for patients of all ages. Specialized offerings at PhysioTherabia include musculoskeletal rehabilitation, neurological rehabilitation with robotics, pediatric rehabilitation, sports injury rehabilitation, spinal and back rehabilitation, and hyperbaric oxygen therapy (HBOT). The centers also aim to champion Saudi Arabia as the region’s hub for all-encompassing sports performance training, management and care for individuals and teams, complementing efforts to integrate the Kingdom into the Exercise is Medicine Global Health Network, managed by the American College of Sports Medicine (ACSM). Burjeel Holdings PLC, a leading super-specialty healthcare services provider in the MENA region listed on the Abu Dhabi Securities Exchange, has unveiled eight new PhysioTherabia centers in Riyadh and four other cities, marking a significant scaling of its geographical footprint across the Kingdom.  The new state-of-the-art facilities are… 

more »KSA: Burjeel Holdings Expands PhysioTherabia Network

BPI: Personalized vaccination against herpes zoster possible

Personalized vaccinations are intended to protect specific population groups from serious diseases. To achieve this, pharmaceutical companies develop special vaccines, modified vaccine doses, and specific vaccination routes in vaccine research. One example is the vaccine against shingles (herpes zoster). This was specifically developed to protect older people. An example of a vaccine specifically developed for older people is the inactivated vaccine against herpes zoster, colloquially known as shingles. The contagious disease, like chickenpox, is caused by varicella-zoster viruses. If you had chickenpox at a younger age, these viruses nest in the nerve cells in the body. About 99.5 percent of people over 50 carry the virus in their nervous system. If the immune system weakens – for example, in older people – these viruses can become active again and cause a painful rash, shingles. The stabbing and burning nerve pain can persist for a long time after the rash subsides. The inactivated vaccine against herpes zoster contains… 

more »BPI: Personalized vaccination against herpes zoster possible

CDC updates respiratory virus recommendations

CDC released today updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19. The new guidance brings a unified approach to addressing risks from a range of common respiratory viral illnesses, such as COVID-19, flu, and RSV, which can cause significant health impacts and strain on hospitals and health care workers. CDC is making updates to the recommendations now because the U.S. is seeing far fewer hospitalizations and deaths associated with COVID-19 and because we have more tools than ever to combat flu, COVID, and RSV. “Today’s announcement reflects the progress we have made in protecting against severe illness from COVID-19,” said CDC Director Dr. Mandy Cohen. “However, we still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory viruses—this includes vaccination, treatment, and staying… 

more »CDC updates respiratory virus recommendations

First Step Toward Early Diagnosis of Metastasis

A team involving the University of Freiburg has developed a new analytical method for the basement membrane in human lungs. Metastases are largely responsible for the death rate of patients with solid cancers; the prognosis of cancer patients reduces significantly if metastases are diagnosed. Till now there was no procedure available to reliably predict the probability of future metastases. A team of scientists from Denmark and Germany led by Junior-Professor Dr. Raphael Reuten from the Medical Faculty at the University of Freiburg and Professor Hauke Clausen-Schaumann from Munich University of Applied Sciences (HM) has now taken the first step toward early diagnosis of metastasis formation: they have developed a user-friendly method for analysing the basement membrane in the human body – because its mechanical properties are a crucial factor during the metastatic process. These results have been published in the renowned scientific journal Nature… 

more »First Step Toward Early Diagnosis of Metastasis

Schweizer Aktien Favoriten 2024: Berichtssaison verläuft ernüchternd

Die Unternehmen rapportieren, und in vielen Fällen wurden Erwartungen enttäuscht oder der Ausblick ist nicht inspirierend. Eigentlich ist dieser Lauf der Dinge nicht wirklich überraschend angesichts der zahlreichen belastenden Faktoren, dennoch scheint es, als ob die Marktteilnehmer die Auswirkungen der Krisen auf die Profitabilität der Schweizer Unternehmen unterschätzt haben. Eine Rolle bei der eingetrübten Stimmung […] Schweizer Aktien Favoriten 2024: Berichtssaison verläuft ernüchternd

Lam Research Named One of the 2024 World’s Most Ethical Companies® by Ethisphere

Fremont, Kalif., 4. März 2024 (ots/PRNewswire) – Das zweite Jahr in Folge erhält Lam die jährliche Auszeichnung für sein Engagement für geschäftliche Integrität durch solide Ethik, Compliance und Governance. Lam Research Corp. (NASDAQ: LRCX) gab heute bekannt, dass das Unternehmen die Auszeichnung World“s Most Ethical Companies® 2024 von Ethisphere erhalten hat, einem weltweit führenden Unternehmen […] Lam Research wird von Ethisphere als eines der ethischsten Unternehmen der Welt 2024 ausgezeichnet®

BioVie Inc. Announces Pricing of Public Offering

CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price of $1.00 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.50 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering… 

more »BioVie Inc. Announces Pricing of Public Offering

Medigene Expands Patent Portfolio for iM-TCR Technology

Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

Impfung gegen Krebs: HPV Zwischenbilanz

Der Traum eines jeden Menschen ist es, sich einmal im Leben impfen zu lassen und danach keine Angst mehr vor schrecklichen Krankheiten zu haben. Vor allem Krebs. Natürlich hat die Wissenschaft noch keine universellen Impfstoffe erfunden, aber es gibt dennoch Impfungen gegen mehrere Krebsarten. Genauer gesagt gibt es eine Impfung gegen das humane Papillomavirus (HPV), […] Impfung gegen Krebs. Der Experte erläuterte, wer gegen HPV geimpft werden sollte

Risiko Bioterrorismus Foto Pexelscom

Bioterrorismus Bedrohungsanalyse: BSL-4 Hochsicherheitslabore des Westens angreifbar

Nicht nur in Deutschland sind BSL-4 Hochsicherheitslabore gegen terroristische Angriffe komplett ungeschützt. Auch in den USA lassen sich hochpathogene Erreger mit wenig Aufwand freisetzen. Eine Analyse von LabNews, die auf jahrelangen Recherchen und Daten des von uns herausgegebenen und mittlerweile eingestellten Biotech-Magazins LifeGen.de (2001 – 2018) basiert, liefert schockierende Belege für massive Sicherheitslücken in der westlichen Sicherheitsarchitektur. Der Report erscheint diese Woche in seiner Kurzfassung bei LabNews und ist in seiner Langfassung für 4500 USD ab dem 20.3.2024 ebenfalls über LabNews erhältlich. Vorbestellungen nehmen wir über das Kontaktformular dieser Webseite entgegen. Wir weisen darauf hin, dass wir die Langfassung des Reports nur gegen vorherige Identifikation (Pass oder Personalausweis) der Käufer verkaufen.